Connect Biopharma is trading at $0.99, down 10.24%, with no confirmed catalyst identified for the October 1 decline. - A report cited negative sentiment around clinical progress but identified no verified driver. - September 30 Phase 2 COPD results, including an 81% reduction in treatment failure, preceded the decline and do not establish its cause. - Major indexes were near flat, making broad-market pressure an unclear explanation.